268 related articles for article (PubMed ID: 25769967)
1. High-throughput drug repositioning for the discovery of new treatments for Chagas disease.
Bellera CL; Sbaraglini ML; Balcazar DE; Fraccaroli L; Vanrell MC; Casassa AF; Labriola CA; Romano PS; Carrillo C; Talevi A
Mini Rev Med Chem; 2015; 15(3):182-93. PubMed ID: 25769967
[TBL] [Abstract][Full Text] [Related]
2. In Silico Drug Repositioning for Chagas Disease.
Bellera CL; Alberca LN; Sbaraglini ML; Talevi A
Curr Med Chem; 2020; 27(5):662-675. PubMed ID: 31622200
[TBL] [Abstract][Full Text] [Related]
3. Repositioned Drugs for Chagas Disease Unveiled via Structure-Based Drug Repositioning.
Adasme MF; Bolz SN; Adelmann L; Salentin S; Haupt VJ; Moreno-Rodríguez A; Nogueda-Torres B; Castillo-Campos V; Yepez-Mulia L; De Fuentes-Vicente JA; Rivera G; Schroeder M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233837
[TBL] [Abstract][Full Text] [Related]
4. Computational Drug Repositioning by Target Hopping: A Use Case in Chagas Disease.
Haupt VJ; Aguilar Uvalle JE; Salentin S; Daminelli S; Leonhardt F; Konc J; Schroeder M
Curr Pharm Des; 2016; 22(21):3124-34. PubMed ID: 26873186
[TBL] [Abstract][Full Text] [Related]
5. Infectious diseases. Drug developers finally take aim at a neglected disease.
Leslie M
Science; 2011 Aug; 333(6045):933-5. PubMed ID: 21852468
[No Abstract] [Full Text] [Related]
6. Target-based Screening of the Chagas Box: Setting Up Enzymatic Assays to Discover Specific Inhibitors Across Bioactive Compounds.
Salas-Sarduy E; Niemirowicz GT; José Cazzulo J; Alvarez VE
Curr Med Chem; 2019; 26(36):6672-6686. PubMed ID: 31284853
[TBL] [Abstract][Full Text] [Related]
7. Repositioning of HIV Aspartyl Peptidase Inhibitors for Combating the Neglected Human Pathogen Trypanosoma cruzi.
Sangenito LS; Menna-Barreto RFS; d'Avila-Levy CM; Branquinha MH; Santos ALS
Curr Med Chem; 2019; 26(36):6590-6613. PubMed ID: 31187704
[TBL] [Abstract][Full Text] [Related]
8. Drug discovery for chagas disease: A viewpoint.
Kratz JM
Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
[TBL] [Abstract][Full Text] [Related]
9. Developments on treatment of Chagas disease - from discovery to current times.
Custodio Leite TO
Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2576-2586. PubMed ID: 30964186
[TBL] [Abstract][Full Text] [Related]
10. Computer-guided drug repurposing: identification of trypanocidal activity of clofazimine, benidipine and saquinavir.
Bellera CL; Balcazar DE; Vanrell MC; Casassa AF; Palestro PH; Gavernet L; Labriola CA; Gálvez J; Bruno-Blanch LE; Romano PS; Carrillo C; Talevi A
Eur J Med Chem; 2015 Mar; 93():338-48. PubMed ID: 25707014
[TBL] [Abstract][Full Text] [Related]
11. Current trends in the pharmacological management of Chagas disease.
Ribeiro V; Dias N; Paiva T; Hagström-Bex L; Nitz N; Pratesi R; Hecht M
Int J Parasitol Drugs Drug Resist; 2020 Apr; 12():7-17. PubMed ID: 31862616
[TBL] [Abstract][Full Text] [Related]
12. Therapeutical approaches under investigation for treatment of Chagas disease.
Bahia MT; Diniz Lde F; Mosqueira VC
Expert Opin Investig Drugs; 2014 Sep; 23(9):1225-37. PubMed ID: 24855989
[TBL] [Abstract][Full Text] [Related]
13. Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies.
Palos I; Lara-Ramirez EE; Lopez-Cedillo JC; Garcia-Perez C; Kashif M; Bocanegra-Garcia V; Nogueda-Torres B; Rivera G
Molecules; 2017 Jun; 22(6):. PubMed ID: 28629155
[TBL] [Abstract][Full Text] [Related]
14. Challenges in Chagas Disease Drug Discovery: A Review.
Paucar R; Moreno-Viguri E; Pérez-Silanes S
Curr Med Chem; 2016; 23(28):3154-3170. PubMed ID: 27356544
[TBL] [Abstract][Full Text] [Related]
15. Current advances in drug discovery for Chagas disease.
Scarim CB; Jornada DH; Chelucci RC; de Almeida L; Dos Santos JL; Chung MC
Eur J Med Chem; 2018 Jul; 155():824-838. PubMed ID: 30033393
[TBL] [Abstract][Full Text] [Related]
16. Trypanothione Reductase: A Target for the Development of Anti- Trypanosoma cruzi Drugs.
Vázquez K; Paulino M; Salas CO; Zarate-Ramos JJ; Vera B; Rivera G
Mini Rev Med Chem; 2017; 17(11):939-946. PubMed ID: 28302040
[TBL] [Abstract][Full Text] [Related]
17. Computational Drug Repositioning for Chagas Disease Using Protein-Ligand Interaction Profiling.
Juárez-Saldivar A; Schroeder M; Salentin S; Haupt VJ; Saavedra E; Vázquez C; Reyes-Espinosa F; Herrera-Mayorga V; Villalobos-Rocha JC; García-Pérez CA; Campillo NE; Rivera G
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560043
[TBL] [Abstract][Full Text] [Related]
18. Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment.
Menna-Barreto RF; de Castro SL
Curr Top Med Chem; 2017; 17(10):1212-1234. PubMed ID: 27784255
[TBL] [Abstract][Full Text] [Related]
19. Lead identification to clinical candidate selection: drugs for Chagas disease.
Neitz RJ; Chen S; Supek F; Yeh V; Kellar D; Gut J; Bryant C; Gallardo-Godoy A; Molteni V; Roach SL; Khare S; Stinson M; Chatterjee AK; Robertson S; Renslo AR; Arkin M; Glynne R; McKerrow J; Siqueira-Neto JL
J Biomol Screen; 2015 Jan; 20(1):101-11. PubMed ID: 25281737
[TBL] [Abstract][Full Text] [Related]
20. Biological factors that impinge on Chagas disease drug development.
Francisco AF; Jayawardhana S; Lewis MD; Taylor MC; Kelly JM
Parasitology; 2017 Dec; 144(14):1871-1880. PubMed ID: 28831944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]